Oral Solid Dosage CDMO Market Size, Revenue, Trend Report 2026 to 2035
What is Oral Solid Dosage CDMO Market Size ?
Oral Solid Dosage CDMO Market is estimated to grow at a 7.0% CAGR during the forecast period for 2026 to 2035.
Oral Solid Dosage CDMO Market Size, Share & Trends Analysis Distribution by Service Type (Formulation Development, Process Development and Scale-Up, Clinical Trial Manufacturing (Phase I / II / III), Commercial Manufacturing, Packaging, Serialization, and Labelling, Analytical, Stability, and QC Services, Regulatory and CMC Support), By Dosage Form (Immediate-Release Tablets, Modified-Release Tablets (SR / CR / DR / ER / Pulsatile), Coated Tablets (Film, Sugar, Enteric), Hard Capsules (Gelatin and HPMC), Soft Gelatin Capsules, Orally Disintegrating Tablets (ODT), Multiparticulates (Pellets, Beads, Mini-Tablets, MUPS), Granules, Sachets, and Stick Packs, Powders for Oral Suspension, Chewables, Lozenges, and Effervescent Tablets) and Segment Forecasts, 2026 to 2035
Oral solid dosage (OSD) contract development and manufacturing organization (CDMO) services refer to outsourced pharmaceutical development and manufacturing solutions for oral drug products. These include tablets, capsules, granules, powders, sachets, orally disintegrating tablets, and modified-release formulations. These services cover the entire product lifecycle. This ranges from pre-formulation studies to formulation and analytical development, process optimization, clinical trial manufacturing, technology transfer, scale-up, commercial production, packaging, serialization, quality control, and regulatory support. OSD CDMOs have specialized knowledge in complex formulation technologies, high-containment manufacturing, advanced process engineering, and meeting global regulatory standards. This expertise allows pharmaceutical companies to efficiently develop and make both innovative and generic oral medicines. The growing complexity of oral formulations, including controlled-release systems, abuse-deterrent formulations, high-potency oral drugs, and patient-centric dosage forms, has increased the strategic importance of specialized CDMO partners. These partners can provide integrated development and manufacturing capabilities.
The oral solid dosage (OSD) CDMO market includes organizations that offer outsourced development, manufacturing, packaging, analytical testing, and lifecycle management services for pharmaceutical companies throughout the drug development process. The market serves a varied customer base. This includes large multinational pharmaceutical companies, specialty pharmaceutical firms, emerging biotechnology companies, and virtual drug developers looking for flexible manufacturing capacity and technical skills. It provides services for both clinical and commercial production across several therapeutic areas. The market features a wide range of manufacturing technologies, including direct compression, wet and dry granulation, continuous manufacturing, hot-melt extrusion, spray drying, and advanced coating systems. Market participants are continually expanding their global manufacturing capabilities. They invest in digital manufacturing, enhance their high-potency oral dosage infrastructure, and improve end-to-end service offerings through acquisitions and strategic collaborations. This positions OSD CDMOs as essential partners within the global pharmaceutical manufacturing landscape.
Competitive Landscape
Which are the Leading Players in the Oral Solid Dosage CDMO Market?
• Catalent, Inc. (Novo Holdings)
• Lonza Group AG (Capsugel Division)
• Thermo Fisher Scientific / Patheon Pharma Services
• Recipharm AB
• Piramal Pharma Solutions
• Boehringer Ingelheim BioXcellence
• Aenova Group
• Siegfried Holding AG
• CordenPharma International
• Hovione
• Almac Group
• Rottendorf Pharma
• Delpharm
• Famar Group
• Quotient Sciences
• Sterling Pharma Solutions
• Adare Pharma Solutions
• PCI Pharma Services
• Cambrex Corporation
• Alcami Corporation
• UPM Pharmaceuticals
• Pharmaceutics International, Inc.
• AbbVie Contract Manufacturing
• Bora Pharmaceuticals (Taiwan)
• Jubilant Pharmova Limited
• Granules India Limited
• WuXi STA (a WuXi AppTec company)
• Samsung Biologics (OSD Entry)
• Dr. Reddy's Contract Pharmaceutical Services (CPS)
Market Dynamics
Driver
Growing Outsourcing of Oral Solid Dosage Development and Manufacturing
Pharmaceutical and biotechnology companies are increasingly turning to contract development and manufacturing organizations (CDMOs) for the development and production of oral solid dosage (OSD) products. This shift helps them improve efficiency, lower costs, and speed up product launch. Instead of building their own manufacturing plants and specialized formulation capabilities, drug developers use CDMOs that offer complete services. These services include formulation development, process optimization, clinical trial manufacturing, commercial production, analytical testing, packaging, and regulatory support. This model allows companies to concentrate on key areas like drug discovery, clinical development, and commercialization while benefiting from the expertise, regulatory compliance, and scalable manufacturing systems of skilled CDMOs. As pharmaceutical pipelines grow and formulation complexity increases, outsourcing has become a smart strategy for ensuring flexible manufacturing, quicker market entry, and dependable global supply. This approach drives growth in the oral solid dosage CDMO market.
Restrain/Challenge
Stringent Regulatory Compliance and Quality Requirements
OSD CDMOs must follow strict global regulatory standards. These include Good Manufacturing Practices (GMP), data integrity requirements, and quality assurance guidelines from agencies like the FDA, EMA, and other health authorities. To keep product quality consistent across different customers, dosage forms, and manufacturing sites, OSD CDMOs need to invest heavily in quality systems, regulatory compliance, validation, and inspections. Any compliance issues, warning letters, or production problems can cause delays, product recalls, damage to reputation, and loss of customer contracts. This makes regulatory compliance one of the biggest challenges for OSD CDMOs.
Commercial Manufacturing Segment is Expected to Drive the Oral Solid Dosage CDMO Market
The commercial manufacturing segment is expected to lead the oral solid dosage (OSD) CDMO market because it brings in the largest portion of CDMO revenue through high-volume, long-term production contracts. The rise in commercial sales of branded and generic oral drugs, along with the increasing outsourcing of commercial-scale manufacturing to reduce costs, increase production capacity, and meet regulatory standards, keeps driving demand. Furthermore, approved products need ongoing manufacturing throughout their lifecycle, which creates regular revenue opportunities for CDMOs.
Orally Disintegrating Tablets (ODT) Segment is Growing at the Highest Rate in the Oral Solid Dosage CDMO Market
The ODT segment is expected to grow the fastest. This growth is driven by the rising need for patient-focused drug delivery systems that make taking medication easier and improve adherence, especially for pediatric, geriatric, and dysphagic patients. Pharmaceutical companies are also broadening ODT formulations for central nervous system disorders, allergies, and pain management. They are outsourcing development and manufacturing to CDMOs that have special skills in formulation and taste masking.
Why North America Led the Oral Solid Dosage CDMO Market?
North America is set to lead the oral solid dosage (OSD) CDMO market. This is due to many pharmaceutical and biotechnology companies, solid CDMO infrastructure, and a high level of outsourcing for drug development and manufacturing. The region hosts several top CDMOs and enjoys strong regulatory standards, modern manufacturing technologies, and ongoing investments in formulation development and commercial manufacturing. Furthermore, the growing pipeline of small-molecule drugs and the rising demand for oral therapies support North America's strong position in the global OSD CDMO market.
Key Development
• In April 2026, Siegfried completed the acquisition of three small-molecule drug substance manufacturing sites in the U.S. and Australia from an affiliate of SK Capital Partners. The acquisition expanded its global API manufacturing network and strengthened its end-to-end CDMO capabilities, from early-phase development to commercial manufacturing.
Oral Solid Dosage CDMO Market Report Scope:
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 7.0% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Service Type, Dosage Form, Manufacturing Technology, API Potency / Containment Class, Therapeutic Area, Customer Type, Contract Structure, Development Phase and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Catalent, Inc. (Novo Holdings), Lonza Group AG (Capsugel Division), Thermo Fisher Scientific / Patheon Pharma Services, Recipharm AB, Piramal Pharma Solutions, Boehringer Ingelheim BioXcellence, Aenova Group, Siegfried Holding AG, CordenPharma International, Hovione, Almac Group, Rottendorf Pharma |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Market Segmentation:
Oral Solid Dosage CDMO Market by Service Type -
• Formulation Development
• Process Development and Scale-Up
• Clinical Trial Manufacturing (Phase I / II / III)
• Commercial Manufacturing
• Packaging, Serialization, and Labelling
• Analytical, Stability, and QC Services
• Regulatory and CMC Support
Oral Solid Dosage CDMO Market by Dosage Form -
• Immediate-Release Tablets
• Modified-Release Tablets (SR / CR / DR / ER / Pulsatile)
• Coated Tablets (Film, Sugar, Enteric)
• Hard Capsules (Gelatin and HPMC)
• Soft Gelatin Capsules
• Orally Disintegrating Tablets (ODT)
• Multiparticulates (Pellets, Beads, Mini-Tablets, MUPS)
• Granules, Sachets, and Stick Packs
• Powders for Oral Suspension
• Chewables, Lozenges, and Effervescent Tablets
Oral Solid Dosage CDMO Market by Manufacturing Technology -
• Wet Granulation
• Dry Granulation and Roller Compaction
• Direct Compression
• Hot Melt Extrusion
• Spray Drying
• Fluid Bed Processing and Coating
• Compression and Film Coating
• Encapsulation (Powder, Pellet, LFHC)
• Continuous Manufacturing
• 3D Printing
Oral Solid Dosage CDMO Market by API Potency / Containment Class -
• Non-Potent / Standard (OEB 1–3)
• Potent (OEB 4)
• Highly Potent / HPAPI (OEB 5)
• Cytotoxic and Hormonal
Oral Solid Dosage CDMO Market by Therapeutic Area -
• Oncology
• Cardiovascular and Metabolic (including Oral GLP-1, Statins, Anti-Hypertensives)
• Central Nervous System (including Abuse-Deterrent Formulations)
• Anti-Infectives
• Respiratory
• Gastrointestinal
• Pain Management
• Other Therapeutic Areas
Oral Solid Dosage CDMO Market by Customer Type -
• Big Pharma (Top 20)
• Mid-Cap Pharma
• Specialty and Branded-Generic Pharma
• Emerging Biotech and Virtual Companies
• Generic Manufacturers
Oral Solid Dosage CDMO Market by Contract Structure -
• Fee-for-Service
• FTE-Based
• Milestone / Risk-Sharing
• Royalty and Profit-Sharing
Oral Solid Dosage CDMO Market by Development Phase -
• Pre-Clinical / Discovery Support
• Clinical Phase I
• Clinical Phase II
• Clinical Phase III
• Commercial Manufacturing
• Post-Approval Lifecycle Management
Oral Solid Dosage CDMO Market by Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Oral Solid Dosage CDMO Market is estimated to grow at a 7.0% CAGR during the forecast period for 2026 to 2035.
Catalent, Inc. (Novo Holdings), Lonza Group AG (Capsugel Division), Thermo Fisher Scientific / Patheon Pharma Services, Recipharm AB, Piramal Pharma Solutions, Boehringer Ingelheim BioXcellence, Aenova Group, Siegfried Holding AG, CordenPharma International, Hovione, Almac Group, Rottendorf Pharma
Oral Solid Dosage CDMO Market is segmented into Service Type, Dosage Form, Manufacturing Technology, API Potency / Containment Class, Therapeutic Area, Customer Type, Contract Structure, Development Phase and By Region
North America region is leading the Oral Solid Dosage CDMO Market.